Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature. | JCO Precis Oncol | 2023 | 37992259 | PubTator, text mining | PubMed |
| The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. | Cancer Med | 2023 | 37986697 | PubTator, text mining | PubMed |
| STAG2 Regulates Homologous Recombination Repair and Sensitivity to ATM Inhibition. | Adv Sci (Weinh) | 2023 | 37985839 | PubTator, text mining | PubMed |
| Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival. | Cell Commun Signal | 2023 | 37974198 | PubTator, text mining | PubMed |
| Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta? | Transl Cancer Res | 2023 | 37969378 | PubTator, text mining | PubMed |
| Developments in Genetics: Better Management of Ovarian Cancer Patients. | Int J Mol Sci | 2023 | 37958970 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response for Cancer Therapy. | Int J Mol Sci | 2023 | 37958890 | PubTator, text mining | PubMed |
| Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. | Cancers (Basel) | 2023 | 37958398 | PubTator, text mining | PubMed |
| Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing. | Cancers (Basel) | 2023 | 37958392 | PubTator, text mining | PubMed |
| A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis. | Diagnostics (Basel) | 2023 | 37958189 | PubTator, text mining | PubMed |
| Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. | Oncogene | 2023 | 37945748 | PubTator, text mining | PubMed |
| Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments. | Front Oncol | 2023 | 37941557 | PubTator, text mining | PubMed |
| Endometrial Cancer Diagnosed at an Early Stage during Lynch Syndrome Surveillance: A Case Report. | Case Rep Oncol | 2023 | 37933313 | PubTator, text mining | PubMed |
| Prioritizing cardiovascular disease-associated variants altering NKX2-5 and TBX5 binding through an integrative computational approach. | J Biol Chem | 2023 | 37926287 | PubTator, text mining | PubMed |
| Interplay between the DNA damage response and the life cycle of DNA tumor viruses. | Tumour Virus Res | 2023 | 37918513 | PubTator, text mining | PubMed |
| Multiplexed assay of variant effect reveals residues of functional importance in the BRCA1 coiled-coil and serine cluster domains. | PLoS One | 2023 | 37917606 | PubTator, text mining | PubMed |
| Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients. | Cancer Res Commun | 2023 | 37916805 | PubTator, text mining | PubMed |
| Identification and development of Tetra-ARMS PCR-based screening test for a genetic variant of OLA1 (Tyr254Cys) in the human failing heart. | medRxiv | 2023 | 37905026 | PubTator, text mining | PubMed |
| Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort. | Cancers (Basel) | 2023 | 37894428 | PubTator, text mining | PubMed |
| De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? | Cancers (Basel) | 2023 | 37894312 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=18